Immuneering Corporation (IMRX), a late-stage clinical oncology company, on Monday presented promising genetic data from clinical trials of cancer drug Atebimetinib at the annual meeting of the American Association of Cancer Research (AACR).
Atebimetinib is a Deep Cyclic inhibitor of MEK, a pathway that controls cellular proliferation and shows mutations in tumor cells. Currently available inhibitors of such pathways offer temporary benefits, as tumors acquire new mutations in the MAPK pathway. The drug acts by mitigating selective pressure that drives these resistance mechanisms, thus providing more durable anti-tumor activity.
Immuneering presented circulating tumor DNA (ctDNA) data from 123 patients treated with atebimetinib, including 86 patients on atebimetinib monotherapy, and 37 on atebimetinib in combination with chemotherapy. The genetic data indicated that emergent acquired mutations rarely converged on the MAPK pathway, with resistance emerging on non-MAPK pathways. This indicates a minimal early molecular evolution during treatment.
The company provided a guide for first patient dosing in the pivotal Phase 3 MAPKeeper 301 trial for atebimetinib with modified Gemcitabine/nab-Paclitaxel (mGnP) in treating first-line metastatic pancreatic cancer by mid-2026. Additionally, dosing of the first patient in the Phase 2 trial for atebimetinib in treating first-line RAS-mutant non-small cell lung cancer (NSCLC) is expected in the second half of this year.
IMRX closed Monday at $5.53, down 0.54%. In the after-hours market, the stock was at $5.45, down 1.45%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.